SI-BONE stock rose 17.6% to US$23.77 today, extending a strong 30-day run, after investors reacted to fresh Q3 2026 results. The immediate story is simple. The market responded positively to a cleaner loss profile and signs of stronger operating discipline.
For a medical device specialist still reporting a quarterly loss of US$3.6 million, the key takeaway sits in the margin and cash trend. Adjusted EBITDA reached US$3.0 million and year to date operating cash flow turned positive, which shifts the focus from near-term survival to how the business is currently managing operating leverage.
Love SI-BONE's improving cash flow picture but still uneasy about a business that remains loss making? Compare it with our list of profitable peers that pair earnings discipline with healthier balance sheets in the list of solid balance sheet and fundamentals stocks (24 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$55.7 million vs. US$48.7 million (up 14.5%)
- Net Loss (Q3 2026 vs. Q3 2025): loss of US$3.6 million vs. loss of US$4.6 million (loss narrowed 20.8%)
- Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.08 per share vs. loss of US$0.11 per share (per share loss improved 23.7%)
- Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 5.5%, with adjusted EBITDA of US$3.0 million vs. prior year level not disclosed (swing to positive margin)
Tired of wading through dense earnings writeups and rows of figures just to understand SI-BONE? See the company’s full financial picture, including a clear view of its cash flow and balance sheet strength, in an intuitive visual format via our company report for SI-BONE.
SI-BONE Bull Case: Adoption, Spine Platform, Reimbursement
For the upbeat thesis on SI-BONE, the key claim is that physician adoption, product breadth, and payer changes can compound together rather than work in isolation.
"Continued expansion of SI-BONE’s physician base, with 1,715 unique physicians performing procedures in Q2 2026 and higher case volumes among repeat users, points to further utilization gains that can support revenue growth and improved operating leverage."
Q3 data lines up with that story. Active physicians reached about 1,770 and U.S. procedure volumes rose 19.5%. Worldwide revenue grew 14.5% while operating expenses increased 9.7%. Adjusted EBITDA of US$3.0 million and positive year to date operating cash flow show that higher case counts are now feeding into operating leverage.
SI-BONE Bear Case: Recall, Mix, Margin Pressure
On the risk side, critics worry that recall execution, mix shifts, and future cost drag could chip away at the apparent progress.
"The voluntary Class II recall of the iFuse TORQ Implant System, due to certain pelvic fixation screws not meeting sterility assurance standards and still ongoing in October 2026, could disrupt procedures that rely on TORQ, pressure relationships in trauma and SI joint accounts, and create additional costs, which together may weigh on revenue and net margins."
So far, the headline numbers do not show visible damage. Q3 worldwide revenue rose 14.5%, gross margin held near 79.3%, and guidance for 2026 revenue and gross margin around 79% was reaffirmed. Mix did pressure average selling prices, and management flagged modest gross margin headwinds in 2027, so margin risk is delayed rather than dismissed.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all.
Hunt For Quiet Mispricings
SI-BONE recently highlighted how sentiment can adjust when its cash position improves. The real opportunity lies in studying stocks that could be undervalued before the wider market pays attention.
- Company 1 - 42% below our estimate - expands a protective film platform as manufacturing and supply chain changes support higher margin products.
- Company 2 - 17% below our estimate - grows a solar tracker and software platform while new storage and inverter offerings seek to balance project delays.
- Company 3 - 49% below our estimate - pours significant capital into AI infrastructure so ad tools, business messaging and early AI hardware can use compute spending more effectively.
That is three of the list. See all 34 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com